AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Adia Med Inc.
Video analysis: ADIA
All videosNo video analysis for this stock yet. Request one from our team.
News: ADIA
Nasdaq Shareholder Requirements Just Verified By Adia Med
Winter Park, Florida--(Newsfile Corp. - September 8, 2026) - Nasdaq requires companies seeking an initial listing on the Nasdaq Capital Market to have a sufficiently broad public shareholder base. That distribution test includes: At least 300 round-lot holders; A round-lot holder generally meaning a shareholder holding at least 100 unrestricted shares; and Adia Med has just verified that it currently has 361 round-lot holders, or 61 holders above Nasdaq's 300-holder minimum.
From Full Sail to Full-Scale: Adia Med Inc. Assembles Intern Social Media Team
Company converts campus session at Full Sail University into an intern-led content team across YouTube, Meta, TikTok, X, and LinkedIn Winter Park, Florida--(Newsfile Corp. - August 31, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and advanced clinical services, today announced that its introductory innovation session earlier this month at Full Sail University delivered exactly the spark the Company was looking for — and that Adia Med has already assembled a social media team of interns to convert that momentum into a new era of organic marketing. From Full Sail to Full-Scale: Adia Med Inc. Assembles Intern Social Media Team To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/311967_adiamedimage.jpg The session introduced Adia Med's mission, research pipeline, and growth story to a room full of creative talent and opened the door to hands-on collaboration in content, social media, and digital marketing.
Adia Med Inc. Engages Lucosky Brookman LLP as Legal Counsel for Planned NASDAQ Uplisting
Winter Park, Florida--(Newsfile Corp. - August 24, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced that it has entered into an engagement letter with Lucosky Brookman LLP ("Lucosky Brookman") to act as legal counsel in connection with the Company's planned uplisting from the OTC Markets to the NASDAQ Capital Market. Lucosky Brookman LLP To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/310842_screenshot_lb_15_years.jpg Under the engagement letter, Lucosky Brookman will provide services that include the preparation and/or review and filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC"), conducting necessary due diligence related to the registration statement, preparation and filing of responses to SEC comments and any related amendments, preparation and filing of the Company's application for listing of its securities on a nationally recognized securities exchange (including responses to comments and amendments), and assisting with general corporate matters related to the registration statement and listing application.
Adia Med Delivers Record Q2 Results: $485K Revenue, First Net Profit, and Nearly Matches Full-Year 2025 Revenue in First Half
Winter Park, Florida--(Newsfile Corp. - August 13, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and advanced clinical services, today announced financial results for the second quarter ended June 30, 2026, as reported in its Form 10-Q filed with the Securities and Exchange Commission. Inline Viewer: ADIA NUTRITION, INC.
Adia Med Partners with Full Sail University; CEO Larry Powalisz to Present Company and Explore Student Assistance with SEO, Social Media, and Marketing
Winter Park, Florida--(Newsfile Corp. - August 11, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies and biologics, today announced a new educational partnership with Full Sail University. As part of the collaboration, Adia Med Chief Executive Officer Larry Powalisz will present the company at Full Sail's Auditorium on August 13, 2026, at 1:00 p.m.
Adia Med to Host Dinner for Physicians at Christner's Steakhouse on August 5 to Discuss Clinical Studies and Collaboration Opportunities
Winter Park, Florida--(Newsfile Corp. - August 5, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies and biologics, today announced that it will host a private dinner for physicians and investors on Wednesday, August 5, 2026, at 7:00 PM at Christner's Steakhouse. To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/308113_adia_med_x_banner.jpg The dinner will provide an overview of Adia Med's current clinical studies, including its ongoing Autism Spectrum Disorder research study and other regenerative medicine initiatives.
Adia Med Completes Phase 1 and Formally Launches Phase 2 of Autism Spectrum Disorder Clinical Study
Next Cohort of 30 Children to Begin a New Phase 1 Treatment Group on October 1, 2026, as Successive Enrollment Continues Every Three Months Winter Park, Florida--(Newsfile Corp. - July 29, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced two distinct milestones in its Autism Spectrum Disorder (ASD) clinical research study (ClinicalTrials.gov Identifier: NCT07304440): the completion of Phase 1 treatment for the study's first cohort of children, and the formal launch of Phase 2 of the study. Separately, the company confirmed that a new cohort of 30 children will begin its own Phase 1 treatment on October 1, 2026, as part of the study's ongoing, staggered enrollment schedule.
Adia Med Inc. (Formerly Adia Nutrition Inc.) Launches Redesigned Corporate Website
New Platform Now Live, Featuring Expanded Sections on Clinical Studies, Stem Cell Therapies, Aesthetics, Media, Podcasts, Case Studies, and Investor Resources Winter Park, Florida--(Newsfile Corp. - July 15, 2026) - Adia Med Inc. (OTCQB: ADIA), a clinical-stage regenerative medicine company, today announced the launch of its redesigned corporate website. The redesigned website is now live, with the project still in progress and active changes and improvements currently being made.
